title: [Diagnostic and therapeutic management of helicobacter pylori: a survey among German gastroenterologists in private practice].
abstract: Purpose:The acceptance and realization of clinical guidelines in daily routine practice is unknown. The aim of this study was to evaluate the behaviour of private gastroenterologists in Germany with respect to the diagnostic and therapeutic management of H. pylori infection in times of increasing antibiotic resistance.Methods:Between 12/2014 and 02/2015 a standardized questionnaire with 19 multiple choice questions were sent to 1507 private gastroenterologists in Germany. The data were electronically captured and analyzed using SurveyMonkey.Results:The response rate was 36 % (540 questionnaires). 65 % of responders prescribe first line therapy by themselves and mainly use standard triple therapies. In patients with intolerance to penicillin, 81 % prescribe Italian triple therapy and 19 % prescribe bismuth quadruple therapy. Risk factors for primary clarithromycin resistance (migrational background, previous macrolide exposure) are routinely assessed by only a minority of responders (22 % and 17 %, respectively). Forty-one percent of responders perform eradication control by themselves mainly using a 13C urea breath test (54 %). In second line therapy, 42 % are prescribing bismuth quadruple therapy and 24 % fluoroquinolone triple therapy. After second line therapy, 58 % of responders are performing eradication control by themselves. Of those, 70 % always take biopsies for antibiotic susceptibility testing.Conclusions:The results of our survey suggest that most private gastroenterologists in Germany adhere to current guidelines for H. pylori management; however, some relevant deviations seem to exist. Our data might be useful for further developments of clinical guidelines and their communication among the medical community.
authors.affiliation: Magen-Darm-Zentrum, Facharztzentrum Eppendorf, Hamburg, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Miehlke
authors.affiliation: bng-Verbandsmanagement, Straubing, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Loibl
authors.affiliation: Aptalis Pharma, Berlin, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Meszaros
authors.affiliation: Medizinische Klinik, Ev. Jung-Stilling Krankenhaus, Siegen, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Labenz
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D005260:Female; D000072102:Gastroenterologists / Q000706:statistics & numerical data*; D005858:Germany / Q000453:epidemiology; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D019538:Health Care Surveys; D016481:Helicobacter Infections / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000453:epidemiology; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011331:Private Practice / Q000706:statistics & numerical data
chemical_list: D000900:Anti-Bacterial Agents